UNITED STATES DEPARTMENT OF COMMERCE.
United States Patent and Trademark Office
vol. 1. Approximation of components of the Proceedings of the Commercial C

APPLICATION NO	DITNG DA'H	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
08-875,849	09.08.1992	MICHAEL J. BRISKIN	LK894-04A2 1855.1004- <i>00</i> 2	4411
21005	590 08 14 2002			
HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINIA ROAD P.O. BOX 9133 CONCORD, MA 01742-9133			EXAMINER SCHWADRON, RONALD B	
	145E	02 SQD / 1 E02 SQS)	1641	.10


Please find below and or attached an Office communication concerning this application or proceeding.

RECEIVED

SEP 2 4 2002

TECH CENTER 1600/2900

COPY







UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08 875,840	1		

RECEIVED

SEP 2 4 2002

TECH CENTER 1600/2900

PER NUMB	ER
Δ	APER NUMB

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

The submitted CRF and Sequence listing in paper copy list a priority claim to 08/386857 in mandatory section (1)(vii). However, the preliminary amendment filed 11/19/2001 amends the specification such that priority to 08/386857 is no longer claimed. A new CRF and Sequence listing in paper copy deleting the priority claim to 08/386857 is required.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of



the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Remain Constrained / Constrained Constrain

Ron Schwadron, Ph.D.

Art Unit 1644

Application No.: 08/875849

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

M	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
\[\frac{1}{2}\]	7. Other:
Аp	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

oplicants:

Michael J. Briskin, Douglas J. Ringler, Dominic Picarella

and Walter Newman

Serial No.:

08/875,849

Group Art Unit:

1644

Filed:

September 8, 1997

Examiner:

R. Schwadron

Confirmation No.: 4411

For:

MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF

RECEIVED

SEP 2 4 2002

TECH CENTER 1600/2900

AMENDMENT AND TRANSMITTAL OF THIRD SUBSTITUTE SEQUENCE LISTING

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Sir:

This amendment is submitted in response to the Notice to Comply with Sequence Requirements mailed from the Patent Office on August 14, 2002. A copy of the Notice to Comply is enclosed.

Transmitted herewith is a copy of a Third Substitute "Sequence Listing" in paper form (sheets 1/16 through 16/16) for the above-identified patent application as required

08/875,849 -2-

by 37 C.F.R. §§ 1.825(a) and 1.821(c), and a copy of the Third Substitute "Sequence Listing" in computer readable form as required by 37 C.F.R. §§ 1.825(b) and 1.821(e).

As required by 37 C.F.R. § 1.825(b), the undersigned hereby states that the contents of the Third Substitute "Sequence Listing" in paper form and in the computer readable form submitted herewith are the same and, as required by 37 C.F.R. § 1.825(a), also states that the submission includes no new matter.

Please amend the above-identified application as follows:

In the Specification

Please delete the Second Substitute "Sequence Listing" filed on March 2, 2001 (pages 103-118) and renumber pages 117-130 as pages 103-116. Please insert the attached Third Substitute "Sequence Listing" (sheets 1/16 through 16/16), comprising SEQ ID NOS:1-17, into the above-referenced application.

REMARKS

In the Notice to Comply, the Examiner stated that a new Sequence Listing in paper and CRF that does not contain a priority claim to U.S. Application No. 08/386,857 is required.

The Third Substitute "Sequence Listing" filed herewith has been revised to delete the priority claims to U.S. Application No. 08/386,857. In addition, the correspondence address and telecommunication information on the Third Substitute "Sequence Listing" has been updated.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Robert H. Underwood

Registration No. 45,170

Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: Septemble 14, 2002